Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

New research by the Mahidol Oxford Tropical Medicine Research Unit, explores the potential benefits of a presumptive lateral flow rapid diagnostic test in managing acute non-malarial febrile illness (NMFI) patient care in rural areas of Southeast Asia.

Dr Chris Chew (extreme left) visiting one of the primary health centres in Bangladesh where this putative test is intended to be used.

In rural regions of Cambodia and Bangladesh, where access to advanced medical facilities is limited, diagnosing and treating acute non-malarial febrile illness can be challenging. The workforce skill sets relating to clinical diagnosis and management are variable, and there are numerous causes of non-malarial febrile illness, many of which present with non-specific symptoms.

A team of researchers from MORU aimed to address this issue by evaluating the cost-effectiveness of lateral flow rapid diagnostic tests. The study published in The Lancet Regional Health Southeast Asia found that this presumptive test (as yet undeveloped) could help diagnose patients presenting with fever in Cambodia and Bangladesh in a cost-effective manner.

The test could help reduce hospitalisations and deaths from certain illnesses, which is important. The study used a lot of data from the area and looked at how the test could help reduce the overuse of certain antibiotics. Overall, it suggests this new test be a good value in the right situations, which should encourage more research and possibly adjustments to make it even more effective and affordable.

Dr Christopher Chew, Clinical Researcher at MORU and the lead author of the study said: ‘Developing new diagnostic tests, especially when they are targeted at low- and middle-income countries where financial resources are limited, is high-risk. If a test is likely to be cost-effective, governments may be more inclined to support its purchase and implementation, creating a viable market for innovators to conduct research and development. This paper provides such crucial early economic evidence that policymakers, researchers, and industry can draw on to advance the development of an urgently-needed test for the two most important causes of fever in South and Southeast Asia, based on contemporary data from the largest study of fever in this region.’

Read full paper here: www.thelancet.com/journals/lansea/article/PIIS2772-3682(24)00039-8/fulltext#%20

Similar stories

Building the world's evidence base to tackle drug-resistant tuberculosis

£10 million international research programme launches across India, Kazakhstan, Mozambique, South Africa and Vietnam.

A New Layer of Control for a Decades-Old Leukemia Drug

How cells respond to the leukemia drug 6-thioguanine still holds surprises: A new study, led jointly by researchers from CeMM and the University of Oxford identifies NUDT5 as an unexpected regulator of drug sensitivity and reveals that its role has nothing to do with its enzymatic activity.

Team ATLAS sets out strategy to investigate cancer avoidance as part of Cancer Grand Challenges

A new position paper from team ATLAS sets out plans to build a cancer antibody atlas to investigate why some people avoid cancer, while others develop disease.

Decades old puzzle solved as scientists uncover cause of inflammatory bowel disease

Scientists have identified the missing link between a long-known genetic signal in inflammatory bowel disease and a damaging immune response that switches off the body’s natural control of inflammation - opening the door to faster diagnosis and targeted treatment.

Oxford Bundibugyo ebolavirus vaccine candidate receives CEPI backing

The Coalition for Epidemic Preparedness Innovations (CEPI) has announced today that it will urgently accelerate the development of three investigational vaccines targeting the Bundibugyo ebolavirus that has caused a rapidly spreading epidemic in the Democratic Republic of the Congo (DRC) and neighbouring Uganda, including one being developed by the Oxford Vaccine Group at the University of Oxford.

New study improves early detection of life threatening infection in children across South and South East Asia

A new study published in Nature Medicine suggests that simple, low-cost tools could help health workers identify children at risk of life-threatening infection earlier, improving access to urgent care in across South and South East Asia.